{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:12:59Z","timestamp":1789384379349,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,6,1]]},"DOI":"10.1038\/sj.bmt.1703014","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T15:27:37Z","timestamp":1032276457000},"page":"1113-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Avoiding hepatic veno-occlusive disease: what do we know and where are we going?"],"prefix":"10.1038","volume":"27","author":[{"given":"SI","family":"Bearman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2001,7,6]]},"reference":[{"key":"BF1703014_CR1","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 85: 1995 3005\u20133020","journal-title":"Blood"},{"key":"BF1703014_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Int Med 1993 118: 255\u2013267","journal-title":"Ann Int Med"},{"key":"BF1703014_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/sj.bmt.1701994","volume":"24","author":"HC Toh","year":"1999","unstructured":"Toh HC, McAfee SL, Sackstein R et al. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation Bone Marrow Transplant 1999 24: 891\u2013895","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S1083-8791(99)70006-6","volume":"5","author":"JL Lee","year":"1999","unstructured":"Lee JL, Gooley T, Bensinger W et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome Biol Blood Marrow Transplant 1999 5: 306\u2013315","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1703014_CR5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","volume":"11","author":"SI Bearman","year":"1993","unstructured":"Bearman SI, Anderson G, Mori M et al. Venocclusive disease of the liver. Development of a model for predicting fatal outcome after marrow transplantation J Clin Oncol 1993 11: 1729\u20131736","journal-title":"J Clin Oncol"},{"key":"BF1703014_CR6","first-page":"737","volume":"92","author":"PG Richardson","year":"1998","unstructured":"Richardson PG, Elias AD, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in efficacy without significant toxicity in a high risk population Blood 1998 92: 737\u2013744","journal-title":"Blood"},{"key":"BF1703014_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/hep.1840190515","volume":"19","author":"HM Shulman","year":"1994","unstructured":"Shulman HM, Fisher LB, Schoch HG et al. Venocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatol 1994 19: 1171\u20131181","journal-title":"Hepatol"},{"key":"BF1703014_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/sj.bmt.1701464","volume":"22","author":"B Gordon","year":"1998","unstructured":"Gordon B, Tarantolo S, Ruby E et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation Bone Marrow Transplant 1998 22: 999\u20131003","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/sj.bmt.1701402","volume":"22","author":"H Oh","year":"1998","unstructured":"Oh H, Tahara T, Bouvier M et al. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease Bone Marrow Transplant 1998 22: 675\u2013679","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR10","first-page":"pp\u2009931","volume-title":"The Liver: Biology and Pathobiology, 2nd edn","author":"JJ Gumucio","year":"1988","unstructured":"Gumucio JJ, Chianale J . Liver cell heterogeneity and liver function. In: Arias IM, Jakoby WP, Popper H et al. (eds) The Liver: Biology and Pathobiology, 2nd edn Raven: New York 1988 pp\u2009931\u2013947"},{"key":"BF1703014_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/hep.1840060322","volume":"6","author":"M el Mouelhi","year":"1986","unstructured":"el Mouelhi M, Kauffman FC . Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver Hepatol 6: 1986 450\u2013456","journal-title":"Hepatol"},{"key":"BF1703014_CR12","first-page":"1261","volume":"286","author":"LD DeLeve","year":"1994","unstructured":"DeLeve LD . Dacarbazine toxicity in murine liver cells: a model of hepatic endothial injury and glutathione defense J Pharm Exp Ther 1994 286: 1261\u20131270","journal-title":"J Pharm Exp Ther"},{"key":"BF1703014_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/hep.510240414","volume":"24","author":"LD DeLeve","year":"1996","unstructured":"DeLeve LD . Cellular target of cyclophosphamide toxicity in murine liver: role of glutathione and site of metabolic activation Hepatol 1996 24: 830\u2013837","journal-title":"Hepatol"},{"key":"BF1703014_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hep.510310224","volume":"31","author":"X Wang","year":"2000","unstructured":"Wang X, Kanel GC, DeLeve LD . Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat Hepatol 2000 31: 428\u2013434","journal-title":"Hepatol"},{"key":"BF1703014_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.bmt.1702387","volume":"25","author":"O Ringden","year":"2000","unstructured":"Ringden O, Remberger M, Lehmann S et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation Bone Marrow Transplant 2000 25: 993\u2013996","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/00000658-199202000-00004","volume":"215","author":"RW Hong","year":"1992","unstructured":"Hong RW, Rounds JD, Helton WS et al. Glutamine preserves liver glutathione after lethal hepatic injury Ann Surg 1992 215: 114\u2013119","journal-title":"Ann Surg"},{"key":"BF1703014_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.bmt.1701172","volume":"21","author":"AP Goringe","year":"1998","unstructured":"Goringe AP, Brown S, O'Callaghan U et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy Bone Marrow Transplant 1998 21: 829\u2013832","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/sj.bmt.1701321","volume":"22","author":"SA Brown","year":"1998","unstructured":"Brown SA, Goringe A, Fegan C et al. Parenteral glutamine protects hepatic function during bone marrow transplantation Bone Marrow Transplantation 1998 22: 281\u2013284","journal-title":"Bone Marrow Transplantation"},{"key":"BF1703014_CR19","first-page":"549","volume":"127","author":"HM Shulman","year":"1987","unstructured":"Shulman HM, Gown AM, Nugent DJ . Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded centralvenules Am J Pathol 1987 127: 549\u2013558","journal-title":"Am J Pathol"},{"key":"BF1703014_CR20","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood.V81.12.3458.3458","volume":"81","author":"EM Faioni","year":"1993","unstructured":"Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occuring anticoagulants and bone marrow transplantation: Plasma protein C predicts development of venocclusivedisease of the liver Blood 1993 81: 3458\u20133462","journal-title":"Blood"},{"key":"BF1703014_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.bmt.1702624","volume":"26","author":"S Tanikawa","year":"2000","unstructured":"Tanikawa S, Mori S, Ohhashi K et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study Bone Marrow Transplant 2000 26: 881\u2013886","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR22","first-page":"497","volume":"8","author":"BG Gordon","year":"1991","unstructured":"Gordon BG, Haire W, Kessinger A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma Bone Marrow Transplant 1991 8: 497\u2013502","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.1995.03530160041031","volume":"274","author":"WD Haire","year":"1995","unstructured":"Haire WD, Ruby EI, Gordon BG et al. Multiple organ dysfunction syndrome in bone marrow transplantation J Am Med Assoc 1995 274: 1289\u20131295","journal-title":"J Am Med Assoc"},{"key":"BF1703014_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.bmt.1701445","volume":"22","author":"J-H Lee","year":"1998","unstructured":"Lee J-H, Lee K-H, Kim S et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study Bone Marrow Transplant 1998 22: 883\u2013888","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR25","first-page":"253","volume":"12","author":"L Catani","year":"1993","unstructured":"Catani L, Gugliotta L, Mattioli Belmonte M et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies Bone Marrow Transplant 1993 12: 253\u2013259","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR26","first-page":"39","volume":"5","author":"PL Harper","year":"1990","unstructured":"Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation Bone Marrow Transplantation 1990 5: 39\u201342","journal-title":"Bone Marrow Transplantation"},{"key":"BF1703014_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1600-0609.1998.tb01006.x","volume":"60","author":"T Sudhoff","year":"1998","unstructured":"Sudhoff T, Heins M, Sohngen D et al. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation Eur J Haematol 1998 60: 106\u2013111","journal-title":"Eur J Haematol"},{"key":"BF1703014_CR28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0360-3016(88)90009-0","volume":"14","author":"G Ganem","year":"1998","unstructured":"Ganem G, Saint-Marc Girardin M-F, Kuentz M et al. Venocclusive disease of the liver after allogeneic bone marrow transplantation in man Int J Radiat Oncol Biol Phys 1998 14: 879\u2013884","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF1703014_CR29","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1200\/JCO.1991.9.7.1224","volume":"9","author":"TJ Nevill","year":"1991","unstructured":"Nevill TJ, Barnett MJ, Klingemann H-G et al. Regimen-related toxicity of a bulsulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation J Clin Oncol 1991 9: 1224\u20131232","journal-title":"J Clin Oncol"},{"issue":"6","key":"BF1703014_CR30","doi-asserted-by":"publisher","first-page":"S375","DOI":"10.1016\/S0002-9378(99)70699-X","volume":"180","author":"Jan Rosing","year":"1999","unstructured":"Rosing J, Tans G . Effects of oral contraceptives on hemostasis and thrombosis Am J Obstet Gynecol 180: S375\u2013S382","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"BF1703014_CR31","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","volume":"92","author":"H H\u00e4gglund","year":"1998","unstructured":"H\u00e4gglund H, Remberger M, Klaesson S et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation Blood 1998 92: 4568\u20134572","journal-title":"Blood"},{"key":"BF1703014_CR32","first-page":"407","volume":"5","author":"SI Bearman","year":"1990","unstructured":"Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion heparin for the prevention of hepatic venocclusive disease after bone marrow transplantation Bone Marrow Transplant 1990 5: 407\u2013411","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","volume":"47","author":"L Marsa-Vila","year":"1991","unstructured":"Marsa-Vila L, Gorin NC, Laport JP et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation Eur J Haematol 1991 47: 346\u2013354","journal-title":"Eur J Haematol"},{"key":"BF1703014_CR34","doi-asserted-by":"crossref","unstructured":"Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. 1992 Blood 79: 2834\u20132840","DOI":"10.1182\/blood.V79.11.2834.2834"},{"key":"BF1703014_CR35","first-page":"185","volume":"18","author":"J Rosenthal","year":"1996","unstructured":"Rosenthal J, Sender L, Secola R et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Bone Marrow Transplant 1996 18: 185\u2013191","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/00007890-199604150-00014","volume":"61","author":"R Or","year":"1996","unstructured":"Or R, Nagler A, Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients Transplantation 1996 61: 1067\u20131071","journal-title":"Transplantation"},{"key":"BF1703014_CR37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","volume":"89","author":"SI Bearman","year":"1997","unstructured":"Bearman SI, Lee JL, Baron AE, McDonald GB . Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 1997 89: 1501\u20131506","journal-title":"Blood"},{"key":"BF1703014_CR38","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/sj.bmt.1702069","volume":"24","author":"J Schriber","year":"1999","unstructured":"Schriber J, Milk B, Shaw D et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation Bone Marrow Transplant 1999 24: 1311\u20131314","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR39","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/sj.bmt.1700985","volume":"20","author":"JD Morris","year":"1997","unstructured":"Morris JD, Harris RE, Hashmi R et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation Bone Marrow Transplant 1997 20: 871\u2013878","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR40","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1007\/PL00014344","volume":"158","author":"R Mertens","year":"1999","unstructured":"Mertens R, Brost H, Granzen B, Nowak-Gottl U . Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer Eur J Pediatr 1999 158: (Suppl. 3) S154\u2013S158","journal-title":"Eur J Pediatr"},{"key":"BF1703014_CR41","first-page":"2510","volume":"96","author":"PG Richardson","year":"2000","unstructured":"Richardson PG, Murakami C, Warren DL et al. Multi-institutional emergency use of defibrotide in 75 patients post SCT with severe VOD and multisystem organ failure: Response without significant toxicity in a high risk population Blood 2000 96: (Suppl. 1) 2510","journal-title":"Blood"},{"key":"BF1703014_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation of veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55\u201361","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703014_CR43","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225\u2013230","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","volume":"20","author":"P Ljungman","year":"1997","unstructured":"Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909\u2013913","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR45","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31\u201342","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00688324","volume":"37","author":"G Vassal","year":"1996","unstructured":"Vassal G, Koscielny S, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation Cancer Chemother Pharmacol 1996 37: 247\u2013253","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703014_CR47","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1200\/JCO.1996.14.5.1484","volume":"14","author":"JT Slattery","year":"1996","unstructured":"Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 1996 14: 1484\u20131494","journal-title":"J Clin Oncol"},{"key":"BF1703014_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","volume":"6","author":"BS Andersson","year":"2000","unstructured":"Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study Biol Blood Marrow Transplant 2000 6: 548\u2013554","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1703014_CR49","doi-asserted-by":"crossref","first-page":"516a","DOI":"10.1182\/blood.V92.2.516.414k11_516_519","volume":"92","author":"WP Vaughan","year":"1998","unstructured":"Vaughan WP, Cagnoni P, Fernandez H et al. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan containing preparative regimen for hematopoietic stem cell transplantation Blood 1998 92: (Suppl. 1) 516a","journal-title":"Blood"},{"key":"BF1703014_CR50","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V75.4.1011.1011","volume":"75","author":"E Holler","year":"1990","unstructured":"Holler E, Kolb H-J, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation Blood 1990 75: 1011\u20131016","journal-title":"Blood"},{"key":"BF1703014_CR51","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/sj.bmt.1701023","volume":"20","author":"C Ferra","year":"1997","unstructured":"Ferra C, de Sanjose S, Lastra CF et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications Bone Marrow Transplant 1997 20: 1075\u20131080","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR52","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2141.1993.tb03348.x","volume":"85","author":"J Tanaka","year":"1993","unstructured":"Tanaka J, Imamura M, Kasai M et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation Br J Haematol 1993 85: 558\u2013565","journal-title":"Br J Haematol"},{"key":"BF1703014_CR53","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/00007890-199512000-00018","volume":"60","author":"M Remberger","year":"1995","unstructured":"Remberger M, Ringden O . Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation Transplantation 1995 60: 1293\u20131299","journal-title":"Transplantation"},{"key":"BF1703014_CR54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bmt.1702209","volume":"25","author":"H Khoury","year":"2000","unstructured":"Khoury H, Adkins D, Brown R et al. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant 2000 25: 737\u2013743","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR55","first-page":"383","volume":"18","author":"S Testa","year":"1996","unstructured":"Testa S, Manna A, Porcellini A et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation Bone Marrow Transplant 1996 18: 383\u2013388","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR56","first-page":"277","volume":"17","author":"L Catani","year":"1996","unstructured":"Catani L, Gugliotta L, Vianelli N et al. Endothelium and bone marrow transplantation Bone Marrow Transplant 1996 17: 277\u2013280","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR57","first-page":"219a","volume":"90","author":"P Richardson","year":"1997","unstructured":"Richardson P, Hoppensteadt D, Elias A et al. Elevation of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1) levels in stem cell transplant (SCT)-associated veno-occlusive disease Blood 1997 90: (Suppl. 1) 219a","journal-title":"Blood"},{"key":"BF1703014_CR58","first-page":"747","volume":"14","author":"C Salat","year":"1994","unstructured":"Salat C, Holler E, Reinhardt B et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease Bone Marrow Transplant 1994 14: 747\u2013750","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR59","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","volume":"89","author":"C Salat","year":"1997","unstructured":"Salat C, Holler E, Kolb H-J et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 1997 89: 2184\u20132188","journal-title":"Blood"},{"key":"BF1703014_CR60","first-page":"955","volume":"18","author":"S Richard","year":"1996","unstructured":"Richard S, Seigneur M, Blann A et al. Vascular endothelial lesion in patients undergoing bone marrow transplantation Bone Marrow Transplant 1996 18: 955\u2013959","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR61","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1378\/chest.101.5.1257","volume":"101","author":"SW Crawford","year":"1992","unstructured":"Crawford SW, Fisher L . Predictive value of pulmonary function tests before marrow transplantation Chest 1992 101: 1257\u20131264","journal-title":"Chest"},{"key":"BF1703014_CR62","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/sj.bmt.1701225","volume":"21","author":"G Manute-Bello","year":"1998","unstructured":"Manute-Bello G, McDonald GB, Hinds MS et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation Bone Marrow Transplant 1998 21: 1125\u20131130","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR63","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJM199304223281620","volume":"328","author":"SL Friedman","year":"1993","unstructured":"Friedman SL . The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies New Engl J Med 1993 328: 1828\u20131835, 1993","journal-title":"New Engl J Med"},{"key":"BF1703014_CR64","first-page":"597A","volume":"26","author":"AE Scanga","year":"1997","unstructured":"Scanga AE, Schrum LW, Iozzo RV et al. Transcriptional regulation of the biglycan gene Hepatol 1997 26: (Suppl.) 597A","journal-title":"Hepatol"},{"key":"BF1703014_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1046\/j.1365-2559.1999.00569.x","volume":"34","author":"Y Sato","year":"1999","unstructured":"Sato Y, Asada Y, Hara S et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation Histopathology 1999 34: 66\u201370","journal-title":"Histopathology"},{"key":"BF1703014_CR66","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0140-6736(93)91646-4","volume":"342","author":"M Eltumi","year":"1993","unstructured":"Eltumi M, Trivedi P, Hobbs JR et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum amino-propeptide of type III procollagen Lancet 1993 342: 518\u2013521","journal-title":"Lancet"},{"key":"BF1703014_CR67","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1182\/blood.V83.10.3036.3036","volume":"83","author":"M Heikinheimo","year":"1994","unstructured":"Heikinheimo M, Halili R, Fasth A . Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Blood 1994 83: 3036\u20133040","journal-title":"Blood"},{"key":"BF1703014_CR68","first-page":"471","volume":"11","author":"B Rio","year":"1993","unstructured":"Rio B, Bauduer F, Arrago JP, Zittoun R . N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin Bone Marrow Transplant 1993 11: 471\u2013472","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR69","first-page":"452A","volume":"26","author":"D Schuppan","year":"1997","unstructured":"Schuppan D, Farrand A, Oesterling C et al. Circulating markers of hepatic fibrosis predict evolution of venocclusive disease after marrow transplantation Hepatol 1997 26: (Suppl.) 452A","journal-title":"Hepatol"},{"key":"BF1703014_CR70","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood.V94.11.3941","volume":"94","author":"J Cavet","year":"1999","unstructured":"Cavet J, Middleton PG, Segall M et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants Blood 1999 94: 3941\u20133446","journal-title":"Blood"},{"key":"BF1703014_CR71","first-page":"584a","volume":"96","author":"WD Haire","year":"2000","unstructured":"Haire WD, Cavet J, Pavletic SZ et al. Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation Blood 2000 96: (Suppl. 1) 584a","journal-title":"Blood"},{"key":"BF1703014_CR72","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","volume":"128","author":"JH Essell","year":"1998","unstructured":"Essell JH, Schroeder MT, Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial Ann Intern Med 1998 128: 975\u2013981","journal-title":"Ann Intern Med"},{"key":"BF1703014_CR73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","volume":"64","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Tanabe J, Watanabe R et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation Am J Hematol 2000 64: 32\u201338","journal-title":"Am J Hematol"},{"key":"BF1703014_CR74","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1248\/bpb.21.240","volume":"21","author":"H Ishida","year":"1998","unstructured":"Ishida H, Nakayasu H, Nukaya H, Tsuji K . Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizopriondon acutus. II. Prophylactic effect of scymnol on lesion development in a rat peripheral arterial occlusion model Biol Pharm Bull 1998 21: 240\u2013244","journal-title":"Biol Pharm Bull"},{"key":"BF1703014_CR75","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0016-5085(98)70377-4","volume":"115","author":"MG Neuman","year":"1998","unstructured":"Neuman MG, Shear NH, Bellentani S, Tiribelli C . Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells Gastroenterol 1998 115: 157\u2013166","journal-title":"Gastroenterol"},{"key":"BF1703014_CR76","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/hep.510240321","volume":"24","author":"MW Fried","year":"1996","unstructured":"Fried MW, Connaghan DG, Sharma S et al. Transjugular intrahepatic portosystemic shunt for the management of severe venocclusive disease following bone marrow transplantation Hepatol 1996 24: 588\u2013591","journal-title":"Hepatol"},{"key":"BF1703014_CR77","first-page":"536","volume":"81","author":"J de la Rubia","year":"1996","unstructured":"de la Rubia J, Carral A, Montes H et al. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS) Haematologica 1996 81: 536\u2013539","journal-title":"Haematologica"},{"key":"BF1703014_CR78","first-page":"643","volume":"18","author":"FO Smith","year":"1996","unstructured":"Smith FO, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease Bone Marrow Transplant 1996 18: 643\u2013646","journal-title":"Bone Marrow Transplant"},{"key":"BF1703014_CR79","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/sj.bmt.1702386","volume":"25","author":"D Azoulay","year":"2000","unstructured":"Azoulay D, Castaing D, Lemoine A et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation Bone Marrow Transplant 2000 25: 987\u2013992","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703014","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:10:16Z","timestamp":1648073416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,6,1]]}},"alternative-id":["BF1703014"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703014","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6,1]]},"assertion":[{"value":"8 February 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}